Roquefort Therapeutics (LON:ROQ) Shares Up 13% – Should You Buy?

Roquefort Therapeutics plc (LON:ROQ) traded up 13% on Wednesday . The stock traded as high as GBX 1.40 and last traded at GBX 1.30. 1,295,074 shares changed hands during trading, an increase of 25% from the average session volume of 1,034,176 shares. The stock had previously closed at GBX 1.15.

Roquefort Therapeutics Stock Performance

The company has a 50 day moving average price of GBX 1.46 and a 200-day moving average price of GBX 1.65. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The company has a market cap of £2.29 million, a P/E ratio of -2.22 and a beta of 0.05.

Insiders Place Their Bets

In other Roquefort Therapeutics news, insider Dr Darrin Disley bought 5,000,000 shares of the firm’s stock in a transaction on Friday, November 21st. The shares were purchased at an average price of GBX 170 per share, for a total transaction of £8,500,000. 23.53% of the stock is owned by company insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.